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Abstract
Hereditary persistence of fetal hemoglobin is an uncommon, benign
disorder in which the expression of g-globin genes persists into adult
life. Several point mutations have been associated with the increased
g-globin gene promoter activity. We evaluated the -195 (C®G) muta-
tion by a functional in vitro assay based on the luciferase reporter gene
system. The results indicated that the increased promoter activity
observed in vivo could not be reproduced in vitro under the conditions
employed, suggesting that other factors may be involved in the over-
expression of the g-globin gene containing the -195 (C®G) mutation.
Furthermore, this is the first time that the -195 (C®G) mutation of the
Ag-globin gene has been evaluated by in vitro gene expression.
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Nondeletional hereditary persistence of
fetal hemoglobin (HPFH) is a condition char-
acterized by a continuous expression of g-
globin genes during adult life. This increase
is associated with specific single-base muta-
tions in the promoter region of either the Gg-
or Ag-globin gene (1). These point mutations
are clustered in three distinct regions of the
5-flanking DNA of the affected g-globin
genes (2).
The complex mechanism of g-globin gene
control regulation is thought to be a conse-
quence of the binding modification of a num-
ber of different trans-acting factors to criti-
cal regions of the g-globin gene promoters,
the cis-elements. The mutations may prevent
the binding of negative regulatory factors or
enhance the binding of positive regulatory
factors, thus interfering with gene expres-
sion. The mechanism by which the muta-
tions cause up-regulation of the g-globin gene
promoter might be of considerable practical
value, as it could lead to the development of
methods to increase the levels of functional
fetal hemoglobin in patients with hemoglo-
binopathies.
A C®G substitution was identified in a
Brazilian individual (3) and, more recently,
another six individuals (three unrelated and
three members of a family) were identified in
which the presence of a -195 (C®G) muta-
tion was closely associated with the high
fetal hemoglobin phenotype (4). The effect
of this mutation has not yet been assessed in
functional assays and this is the first time that
this mutation has been evaluated by in vitro
gene expression. In the present study we
used the reporter gene approach based on the
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luciferase gene to assess the effect of a -195
(C®G) mutation in the Ag-globin gene pro-
moter.
The results indicated that the observed in
vivo phenotype of high fetal hemoglobin lev-
els cannot be translated into increased in vitro
promoter function when compared to the wild-
type promoter under the experimental condi-
tions described, suggesting that in addition
to the mutation other factors are involved in
controlling the promoter function.
A blood sample was collected in EDTA
and DNA was isolated by the method of
Poncz et al. (5). The Ag promoter of 675 bp
was prepared by polymerase chain reaction
(PCR) amplification from a control and a
patient with C®G mutation at position -195
using genomic DNA as template and the
primers P 133 and P 134 (Table 1), which
were engineered to contain an XhoI (forward
primer) or a HindIII site (reverse primer) at
their 5 ends (Table 1).
PCR mutagenesis was used to generate a
377-bp fragment of the PCR products con-
taining the T®C mutation at position -175 in
three stages as described by Motum et al. (6).
Stage 3 was modified to include primers P 6
and P 134 (Table 1), engineered to contain
an XhoI (forward primer) or a HindIII site
(reverse primer) at their 5 ends.
All samples were denatured at 95oC for 10
min before adding the Taq DNA polymerase
enzyme (Gibco, Grand Island, NY, USA) and
then amplified for 30 cycles with denaturation
at 94oC for 1 min, annealing at 55oC for 1 min
and extension at 72oC for 1 min in an auto-
mated PTC 200 thermal cycler (M.J. Re-
search Inc., Watertown, MA, USA), followed
by a final extension at 72oC for 10 min.
PCR products were double-digested with
XhoI and HindIII. The purified products were
identified by 1% agarose gel electrophoresis
with TAE buffer and stained with the fluo-
rescent dye ethidium bromide (7). The pro-
moters prepared as described above were
inserted into the XhoI-HindIII sites of the
pGL2-Basic (Promega, Madison, WI, USA),
a promoterless luciferase reporter gene vec-
tor.
Supercoiled plasmid DNA prepared for
transfection was grown in Escherichia coli
strain DH5a (Bethesda Research Laborato-
ries, Bethesda, MD, USA) and purified with
a cesium chloride density gradient (7). At least
two different plasmid preparations of each
construct were used for transfection. For all
experiments, the integrity and concentrations
of all plasmids to be transfected were verified
by 1% agarose gel electrophoresis and the
concentration and purity was evaluated by
spectrophotometry at 260/280 nm.
All the g-globin gene promoter constructs
were sequenced using the Sequenase kit
(United States Biochemical Corporation,
Cleveland, OH, USA) and primers GL1 and
GL2 of the pGL2 expression vector (Pro-
mega) to verify the correctness of the ampli-
fied promoter segment and its appropriate
insertion into the pGL2-Basic vector, and
correct insertion and sequence of the Ag-
globin gene promoter construct were con-
firmed by sequencing.
K562 cells (8) were maintained in RPMI
1640 medium supplemented with 10% fetal
calf serum (Gibco), at 37oC and 5% CO2.
The cells were transfected with 20 µg of g-
globin gene promoter luciferase constructs
and 5 µg of SV40/ß-galactosidase expres-
sion vector (Promega), which was used as an
internal control for transfection efficiency,
by electroporation in a Gene Pulser (Bio-
Table 1 - Ag-Globin oligonucleotide primers for PCR.
1Underlined bases added to produce an XhoI site (sense primer). 2Un-
derlined bases added to produce a HindIII site (antisense primer). *Mu-
tated base to produce -175 (T®C) base substitution. S, Sense; AS,
antisense.
Primer Location Sequence (5'®3')
P 133 -622 to -591 ATCTCGAGTGAAACTGTGGTCTTTATGA1
P 6 -324 to -305 ATCTCGAGCTATGATGGGAGAAGGAAAC1
P 134  +33 to +53 CTAAGCTTTCTGGACTAGGAGCTTATTG2
-175 S -186 to -165 CTCAATGCAAAC*ATCTGTCTG
-175 AS -186 to -165 CAGACAGATG*TTTGCATTGAG
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Rad Laboratories, Richmond, CA, USA) as
described by Motum et al. (6). Luciferase
assays were performed using the Luciferase
Assay System (Promega) as recommended
by the manufacturer and light emission was
measured with a luminometer monolight
2010 (Analytical Luminescence Laboratory,
San Diego, CA, USA). The luciferase activ-
ity associated with each construct was cor-
rected for differences in transfection effi-
ciency based on the results of the ß-galac-
tosidase assay (9). All transfections were
performed at least in triplicate and repeated
several times.
Data are reported as mean – SD. Groups
were compared by standard analysis of vari-
ance (ANOVA).
The results of the transfection studies are
summarized in Table 2. As expected, the
-175 (T®C) site-directed mutation increased
the expression of the Ag-globin gene pro-
moter construct by 2.2-fold compared to the
wild-type sequence (activity 1.0) in K562.
The construct containing the -195 (C®G)
mutation was compared with the wild-type
Ag-globin gene promoter construct (activity
1.0) and was not significantly different in
K562 (Table 2). The promoterless luciferase
(pGL2) activity was 30-fold less than in
other constructs (data not shown).
HPFH is a condition characterized by the
continuous expression of fetal hemoglobin
during adult life. Several mutations in the g-
globin promoter have been described. How-
ever, their contribution to the phenotype re-
mains poorly understood. In the present study,
we used a luciferase reporter gene approach
to determine the effect of the -195 (C®G)
mutation in the Ag-globin promoter on the
K562 cell line, using the -175 (T®C) muta-
tion in the Ag-globin promoter as a positive
control.
Several studies have demonstrated up-
regulation of the -175 (T®C) mutation (6).
We used this mutation as a positive control
in order to determine the ability of this sys-
tem to reproduce the up-regulation of a Ag-
globin gene promoter luciferase construct in
vitro. Our analysis showed that this con-
struct containing the -175 site-directed mu-
tation is able to increase luciferase expres-
sion, with a two-fold higher expression than
the wild-type sequence. This mutation was
in a conserved octamer position in the g-
globin gene promoter and was recognized by
the ubiquitously distributed octamer-bind-
ing protein (OBP). Ottolenghi et al. (10)
showed that the -175 (T®C) mutation abol-
ishes binding of the OBP and therefore, in its
absence, the ability of erythroid-specific
GATA proteins to bind adjacent sites on
both sides of the octamer is increased. In our
studies, we observed that this mutation led to
a two-fold higher promoter function. These
results were consistent with previous data,
which reported an increase of 2.5- to 5-fold
(11-13). The increment in promoter strength
observed in our studies and others was much
less than the in vivo 50 to 100 up-regulation
of the mutated HPFH gene (11).
Our analysis of the HPFH-associated g-
globin gene promoter containing the -195
(C®G) mutation was not translated into in-
creased promoter function in transient ex-
pression assays. The failure to detect up-
regulation by this mutation, however, did
not preclude the potential role of this muta-
tion in altering g-globin gene expression,
since several other nondeletional HPFH mu-
tations, including the -202 and -196, were
not overexpressed in the transient expres-
sion system (14,15).
Table 2 - Ratio of luciferase/ß-galactosidase activity (relative to wild type) of
Ag-globin with the -195 (C®G) and -175 (T®C) mutation in the K562 cell
line.
The estimate is reported as mean ± SD. CI: Confidence interval; N: number
of assays performed. *P<0.05 compared to wild type (Student t-test).
Construct Estimate 95% CI N
Wild type 1.0 64
-175 (T®C) 2.19 ± 0.26* 1.90-2.46 25
-195 (C®G) 1.06 ± 0.05 0.98-1.14 39
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Ulrich et al. (16) suggested that point
mutations at positions -202, -196 and -195
reduce triplex stability by disrupting critical
Hoogsteen base pairs and the -198 substitu-
tion is the only HPFH mutation in the g-200
region that does not destabilize the second-
ary DNA structure. The -198 (C®T) muta-
tion increases g-globin promoter strength in
transiently transfected fetal erythroid cells
or an in vitro transcription assay, while the
-202 and -196 substitutions do not.
These results suggest that the phenotype
observed in vivo is not only dependent on the
trans-acting factor/cis-acting element alter-
ation but is also dependent on DNA struc-
ture modifications, which may be difficult to
reproduce in vitro. Another factor that may
affect g-globin expression in vitro and was
not used in our experiments is the locus
control region (LCR). Over the last decade,
the importance of the LCR has been well
documented (17). Recently, Langdon and
Kaufman (18) studied the elements required
for interaction of the g-globin promoter with
5HS2 in the K562 cell line. They demon-
strated that the HPFH g-globin promoter
linked to 5HS2 showed a two- to three-fold
higher expression than the wild-type pro-
moter.
In this paper, we report that the in vitro
functional activity of the Ag-globin promoter
containing the -195 (C®G) point mutation
is not different from the wild-type promoter
and that other in vitro and in vivo studies
including this mutation and the sequences of
the LCR would clarify the effect of the HPFH
point mutation and this control region on the
expression of the g-globin genes.
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